Canakinumab

(Ilaris)

Canakinumab

Drug updated on 10/23/2023

Dosage FormInjection (subcutaneous: 150 mg/ml)
Drug ClassInterleukin-1β blocker
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of periodic fever syndromes.
  • For the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: Familial Cold Auto-inflammatory Syndrome (FCAS); Muckle-Wells Syndrome (MWS)
  • For the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients.
  • For the treatment of Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients.
  • For the treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients.
  • For the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.